A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Umeclidinium/vilanterol (Primary) ; Salmeterol; Umeclidinium
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jul 2017 Planned End Date changed from 27 Jun 2018 to 11 Jul 2018.
    • 06 Jul 2017 Planned primary completion date changed from 27 Jun 2018 to 11 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top